SHOCKING: Luke miels - You Need To See This

GSK shares dive as weaker vaccine sales unnerve investors

British pharma company one of biggest fallers on FTSE 100 despite better than expected financial results

The Guardian - UK · Oct 28

GSK sees falling vaccine sales take shine off earnings

The drugs giant revealed vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles and RSV jabs.

Evening Standard · Oct 28

GSK heads to Cambridge with long-awaited positive vibes

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders

The Guardian - UK · Jul 28

Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise

The Guardian - UK · Mar 5

GSK, take two: the bullish tone at the top is finally more convincing

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential

The Guardian - UK · Feb 4

GSK posts higher profits but indicates sales growth to slow in 2026

It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year.

Evening Standard · Feb 4

FTSE 100 Live 04 February: GSK milestone as index soars to new record, AI data jitters continue

GSK results today helped shares surge above 2000p for the first time in over two decades as the FTSE 100 index set a new intraday record.

Evening Standard · Feb 4

Drugs giant to axe up to 350 R&D jobs across the US and UK

About 50 jobs will be impacted in the group’s main UK R&D hub in Stevenage, Hertfordshire

The Independent UK · Feb 2

GSK cutting jobs in UK and US as part of ongoing R&D changes

It is understood around 50 UK jobs so far are being cut in the group’s main UK R&D hub in Stevenage, Hertfordshire.

Evening Standard · Feb 2

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.

Benzinga · Sep 29, 2025